WeightWatchers to exit process to cut $1.15 billion debt next week
WW is exiting bankruptcy, cutting $1.15 billion in debt next week.
View signal analysisCompany intelligence
WW
WW International, Inc. · NASDAQ · Consumer Cyclical
Price$13.72-11.25% · −$1.74
Market cap137.18MEquity value
P / E-2.9Trailing ratio
Volume511.97KLatest session
Market data
TradingViewWW price chart
Related signals
1 min delayedLatest WW price-moving signals
Browse public WW signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Wellness companies eager to avoid WeightWatchers' fate embrace weight-loss drugs
WeightWatchers declared bankruptcy due to increased competition from weight-loss drugs. Health and wellness companies are adapting to avoid similar outcomes.
View signal analysisWeightWatchers Files for Bankruptcy to Reduce Debt Amid Rising Obesity Drug Use, Stock Drops
WeightWatchers plans to file for Chapter 11 bankruptcy. Declining demand for obesity drugs impacts the company's performance significantly. Shares have dropped nearly 40% due to restructuring efforts. The company seeks reduced debt and improved operational flexibility. Current operations remain unaffected despite upcoming bankruptcy filing.
View signal analysisWW, known as Weight Watchers, files for bankruptcy and the stock plunges
WW International Inc. filed for bankruptcy amid significant debt challenges. Shares dropped nearly 50% in premarket trading following the announcement.
View signal analysisWeightWatchers files for bankruptcy amid rising use of Ozempic, other obesity drugs
WW International filed for Chapter 11 bankruptcy to cut $1.6 billion debt. Shares dropped 40% post-announcement amid struggling traditional weight-loss programs. GLP-1 drugs like Ozempic decreased demand for WW's offerings significantly. The reorganization plan aims to eliminate $1.15 billion in debt. WW’s subscription revenues fell 5.6% year-over-year as financial losses grew.
View signal analysisWeightWatchers files for bankruptcy amid rising use of Ozempic, other obesity drugs
WW International filed for Chapter 11 bankruptcy to reduce $1.6 billion debt. Shares dropped 40% following bankruptcy announcement, reflecting investor panic. Popularity of GLP-1 drugs is disrupting traditional weight-loss demand. Despite a 2018 rebranding to wellness, company continues losing money. Last year, the company reported a $345.7 million loss and declining revenues.
View signal analysisResearch